|
⚲
|
| Keyboard |
| Chickadee Biomedicines Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0002138882 |
| Sale | 2026-06-22 (1.0 M Offered, 0.1 M Sold) |
| Fund | |
| Phone | 6173022620 |
| Address | 91 Oakmere Street Boston, MA 02132-5529 |
| Source | [EDGAR] |
| Amount Raised ($k) |
|---|
| Company Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Form D Offering | |
|---|---|
| Filed | 2026-06-25 (D) |
| Exemption | 506(b) |
| Remaining | $850,000 |
| Duration | One year or less |
| Revenue | Decline to Disclose |
| Directors | Role | 2011 - 2026 |
|---|---|---|
| Mikael Dolsten | Executive Officer | |
| Weining Lu | Executive Officer |
| Comparable Firms | State | AUM |
|---|---|---|
|
Robeco Investment Management Inc
✚
|
MA | |
|
Boston Hill Advisors LLC
✚
|
MA | |
|
Navemar Capital Management LP
✚
|
MA | |
|
Venus Capital Management Inc
✚
|
MA | |
|
Perennial Capital Advisors LLC
✚
|
MA | |
|
Catch Point Rights Partners LP
✚
|
MA | |
|
Boston Partners
✚
|
MA | |
|
Third Rock Ventures LLC
✚
|
MA | |
|
Three BAYS Capital LP
✚
|
MA | |
|
Nextview Management Company LLC
✚
|
MA |